EP 0975605 A1 20000202 - PYRIDAZINE AND PHTHALAZINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS ANTICONVULSANTS
Title (en)
PYRIDAZINE AND PHTHALAZINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS ANTICONVULSANTS
Title (de)
PYRIDAZIN-UND PHTHALAZINDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ANTIKONVULSIVA
Title (fr)
DERIVES DE PYRIDAZINE ET DE PHTALAZINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION COMME ANTI-CONVULSIFS
Publication
Application
Priority
- EP 9802172 W 19980414
- GB 9707693 A 19970416
Abstract (en)
[origin: WO9846574A1] A method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, MS and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction and amyotrophic lateral sclerosis (ALS) comprises administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof in which the ring system Q is pyridazinyl or phthalazinyl; the ring system P is phenyl or pyridyl; R<1> is hydrogen, C1-6 alkyl, phenyl or C1-6 alkylphenyl; R<2> is hydrogen or C1-6 alkyl; R<3> is hydrogen or up to three substituents selected from halogen, CN, trifluoromethyl, trifluoromethoxy, C1-6 alkyl, C1-6 alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, phenyl, phenoxy, phenylC1-4alkyl, benzyloxy, or benzoyl.
IPC 1-7
IPC 8 full level
A61K 31/50 (2006.01); A61K 31/501 (2006.01); A61K 31/502 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 25/06 (2006.01); A61P 25/08 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 43/00 (2006.01); C07D 237/20 (2006.01); C07D 237/34 (2006.01); C07D 401/12 (2006.01)
CPC (source: EP)
A61K 31/50 (2013.01); A61P 25/00 (2017.12); A61P 25/04 (2017.12); A61P 25/06 (2017.12); A61P 25/08 (2017.12); A61P 25/14 (2017.12); A61P 25/16 (2017.12); A61P 25/18 (2017.12); A61P 25/20 (2017.12); A61P 25/22 (2017.12); A61P 25/24 (2017.12); A61P 25/28 (2017.12); A61P 25/30 (2017.12); A61P 43/00 (2017.12); C07D 237/20 (2013.01); C07D 237/34 (2013.01)
Citation (search report)
See references of WO 9846574A1
Designated contracting state (EPC)
BE CH DE ES FR GB IT LI NL
DOCDB simple family (publication)
WO 9846574 A1 19981022; CA 2288171 A1 19981022; EP 0975605 A1 20000202; GB 9707693 D0 19970604; JP 2001518908 A 20011016
DOCDB simple family (application)
EP 9802172 W 19980414; CA 2288171 A 19980414; EP 98920520 A 19980414; GB 9707693 A 19970416; JP 54349098 A 19980414